<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447821</url>
  </required_header>
  <id_info>
    <org_study_id>CB-01-11/03</org_study_id>
    <nct_id>NCT03447821</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea</brief_title>
  <official_title>Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cosmo Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cosmo Pharmaceuticals NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and the preliminary efficacy data on the three doses of the new Cosmo
      Technologies oral rifamycin SV colon-release 200 mg tablets manufactured according to MMX
      technology (CB-01-11) in the treatment of infectious diarrhoea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and the preliminary efficacy data on the three doses of the new Cosmo
      Technologies oral rifamycin SV colon-release 200 mg tablets manufactured according to MMXTM
      technology (CB-01-11) in the treatment of infectious diarrhoea.

      Primary end points to determine:

      • The safety and preliminary efficacy data of the three doses of the new rifamycin SV
      formulation tested based upon the time elapsed from the ingestion of the 1st dose of study
      medication to the passage of the last unformed stool (TLUS), in compliance with the relevant
      guidelines

      Secondary end-points to determine:

        -  The number of patients showing improvement in diarrhoea during a 24-h interval, i.e. &gt;50
           % reduction of bowel movements.

        -  The number of unformed stools passed per 24-h interval, after dosing.

        -  The number of patients who are declared to be &quot;well&quot;. Wellness is defined as the patient
           having 48 hours with no unformed stools, a maximum of two soft stools and no clinical
           symptoms of infectious diarrhoea.

        -  The number of treatment failures. A treatment failure is defined as clinical
           deterioration or worsening of symptoms or illness continuing after 120 h following the
           first dose.

        -  The number and percentage of patients recovered from diarrhoea. Patients were considered
           to have recovered if fewer than three unformed stools were passed in the previous 24
           hours and no symptom of enteric infection were present.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Last Unformed Stool (TLUS)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>The safety and preliminary efficacy data of the three doses of the new rifamycin SV formulation tested based upon the time elapsed from the ingestion of the 1st dose of study medication to the passage of the last unformed stool (TLUS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Showing Improvement in Diarrhoea During a 48h Interval</measure>
    <time_frame>48 hours</time_frame>
    <description>The evaluation of improvement in diarrhoea during a 48 hour interval is defined as a &gt;50% reduction of bowel movements versus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Unformed Stools Passed Per 24-h Interval</measure>
    <time_frame>192 hours</time_frame>
    <description>The number of unformed stools passed per 24-h interval, after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Who Are Declared to be &quot;Well&quot;</measure>
    <time_frame>48 hours</time_frame>
    <description>The patient having must meet all of the following criteria in order to be classified as &quot;well&quot;: 48 hours with no unformed stools with a maximum of two soft stools and no clinical symptoms of infectious diarrhoea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Failure</measure>
    <time_frame>120 hours</time_frame>
    <description>A treatment failure is defined as clinical deterioration or worsening of symptoms or illness continuing after 120 h following the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Recovered From Diarrhoea</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients were considered to have recovered if fewer than three unformed stools were passed in the previous 24 hours and no symptom of enteric infection were present.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Infectious Diarrhoea</condition>
  <arm_group>
    <arm_group_label>400 mg Rifamycin SV dosage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg Rifamycin SV dosage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200 mg Rifamycin SV dosage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg Rifamycin SV dosage</intervention_name>
    <arm_group_label>400 mg Rifamycin SV dosage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800 mg Rifamycin SV dosage</intervention_name>
    <arm_group_label>800 mg Rifamycin SV dosage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1200 mg Rifamycin SV dosage</intervention_name>
    <arm_group_label>1200 mg Rifamycin SV dosage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients had to meet all of the following inclusion criteria:

          -  Male and female patients aged 18-65 years inclusive on the date of screening.

          -  Patients with infectious diarrhoea (ID) in the active phase of no more than 72-h
             duration. Criteria for diagnosis of ID were: three or more unformed stools in the
             preceding 24 hours, and at least one symptom of enteric infection e.g. abdominal
             cramps/pain, tenesmus, urgency, an excess of gas/flatulence, nausea, vomiting.

          -  If female, and of child-bearing potential, use of an effective contraceptive method.
             (Oral contraceptives, injectable hormonal contraceptives, double-barrier method
             (condom/diaphragm with spermicide) and intra-uterine devices, according to the
             definition of Note 3 of ICH M3(M) Guideline. Females were considered not to be of
             child-bearing potential, if they were at least 12 months post-menopausal.

          -  Ability, in the investigator's opinion to comprehend the full nature and purpose of
             the study, including the possible risks and side effects, and willing to comply with
             the requirements of the study.

          -  Patients who have voluntarily signed and dated the informed consent document for
             screening and study specific procedures.

          -  Patients must be sufficiently literate to be able to complete a diary card.

        Exclusion Criteria:

        Patients had not to have had of any of the following:

          -  Females of child-bearing potential not using an effective contraceptive method.

          -  Pregnant or lactating females.

          -  Fever (defined as a body (axillary) temperature ≥ 38° C) present either at the
             screening visit or in the previous 24 hours.

          -  Visible presence of blood in the stool at baseline.

          -  Patients with any history or evidence on examination, of clinically significant
             gastrointestinal (in particular intestinal obstruction and severe intestinal
             ulcerative lesions), renal, hepatic, endocrine, respiratory, cardiovascular,
             dermatological or haematological disease, which in the opinion of the investigator
             could affect the interpretation of the efficacy and safety data.

          -  Patients with moderate or severe dehydration (see Appendix 2 of the protocol, for
             definitions of clinical symptoms).

          -  Prohibited previous and concomitant medication (see relevant section of the protocol).

          -  History of recent gastrointestinal malignancy (within 6 months).

          -  Allergy: presumptive or ascertained hypersensitivity to the study drug, history of
             anaphylaxis or allergic reactions in general.

          -  History of, or current misuse of alcohol, drugs or abuse of medication.

          -  Participation in another study with any investigational product within 3 months before
             screening.

          -  Patients who, in the opinion of the investigator, could be un-cooperative and/or
             non-compliant and should not therefore participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Mancera Reyes</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL CENTRAL DE ORIENTE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Can Polat Eyigün</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gülhane Military Medical Academy</affiliation>
  </overall_official>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <results_first_submitted>February 28, 2018</results_first_submitted>
  <results_first_submitted_qc>February 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infectious diarrhoea</keyword>
  <keyword>rifamycin SV</keyword>
  <keyword>rifamycin SV MMX</keyword>
  <keyword>MMX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Dysentery</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Rifamycin SV</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>None. IPD not to be shared.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>400 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
        </group>
        <group group_id="P2">
          <title>800 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
        </group>
        <group group_id="P3">
          <title>1200 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent To Treat</population>
      <group_list>
        <group group_id="B1">
          <title>400 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
        </group>
        <group group_id="B2">
          <title>800 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
        </group>
        <group group_id="B3">
          <title>1200 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="12.1"/>
                    <measurement group_id="B2" value="37.3" spread="15.9"/>
                    <measurement group_id="B3" value="41.9" spread="12.7"/>
                    <measurement group_id="B4" value="39.6" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.2" spread="9.8"/>
                    <measurement group_id="B2" value="160.8" spread="9.7"/>
                    <measurement group_id="B3" value="159.1" spread="6.2"/>
                    <measurement group_id="B4" value="161.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="16.7"/>
                    <measurement group_id="B2" value="72.9" spread="17"/>
                    <measurement group_id="B3" value="70.3" spread="11.8"/>
                    <measurement group_id="B4" value="71.8" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axillary Temperature (°C)</title>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="0.5"/>
                    <measurement group_id="B2" value="36.8" spread="0.4"/>
                    <measurement group_id="B3" value="36.7" spread="0.4"/>
                    <measurement group_id="B4" value="36.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Last Unformed Stool (TLUS)</title>
        <description>The safety and preliminary efficacy data of the three doses of the new rifamycin SV formulation tested based upon the time elapsed from the ingestion of the 1st dose of study medication to the passage of the last unformed stool (TLUS)</description>
        <time_frame>Up to 7 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O2">
            <title>800 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O3">
            <title>1200 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Last Unformed Stool (TLUS)</title>
          <description>The safety and preliminary efficacy data of the three doses of the new rifamycin SV formulation tested based upon the time elapsed from the ingestion of the 1st dose of study medication to the passage of the last unformed stool (TLUS)</description>
          <population>Intent to Treat</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" spread="12.1"/>
                    <measurement group_id="O2" value="51.4" spread="12.3"/>
                    <measurement group_id="O3" value="57.4" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Showing Improvement in Diarrhoea During a 48h Interval</title>
        <description>The evaluation of improvement in diarrhoea during a 48 hour interval is defined as a &gt;50% reduction of bowel movements versus the baseline value</description>
        <time_frame>48 hours</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O2">
            <title>800 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O3">
            <title>1200 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Showing Improvement in Diarrhoea During a 48h Interval</title>
          <description>The evaluation of improvement in diarrhoea during a 48 hour interval is defined as a &gt;50% reduction of bowel movements versus the baseline value</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Showed improvement within 48 hrs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Showed no improvement within 48 hrs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Unformed Stools Passed Per 24-h Interval</title>
        <description>The number of unformed stools passed per 24-h interval, after dosing</description>
        <time_frame>192 hours</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O2">
            <title>800 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O3">
            <title>1200 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Unformed Stools Passed Per 24-h Interval</title>
          <description>The number of unformed stools passed per 24-h interval, after dosing</description>
          <population>ITT</population>
          <units>Unformed stools</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="2.74"/>
                    <measurement group_id="O2" value="4.67" spread="3.17"/>
                    <measurement group_id="O3" value="4.73" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="1.95"/>
                    <measurement group_id="O2" value="1.5" spread="1.57"/>
                    <measurement group_id="O3" value="2.64" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48-72 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="1.64"/>
                    <measurement group_id="O2" value="1.29" spread="1.6"/>
                    <measurement group_id="O3" value="1.7" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72-96 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.29"/>
                    <measurement group_id="O2" value="1.67" spread="2.08"/>
                    <measurement group_id="O3" value="1.8" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96-120 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.71"/>
                    <measurement group_id="O2" value="1.5" spread="2.12"/>
                    <measurement group_id="O3" value="0.75" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120-144 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0"/>
                    <measurement group_id="O2" value="0.5" spread="0.71"/>
                    <measurement group_id="O3" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144-168 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                    <measurement group_id="O3" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168-192 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                    <measurement group_id="O3" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Who Are Declared to be &quot;Well&quot;</title>
        <description>The patient having must meet all of the following criteria in order to be classified as &quot;well&quot;: 48 hours with no unformed stools with a maximum of two soft stools and no clinical symptoms of infectious diarrhoea.</description>
        <time_frame>48 hours</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O2">
            <title>800 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O3">
            <title>1200 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Who Are Declared to be &quot;Well&quot;</title>
          <description>The patient having must meet all of the following criteria in order to be classified as &quot;well&quot;: 48 hours with no unformed stools with a maximum of two soft stools and no clinical symptoms of infectious diarrhoea.</description>
          <population>intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Wellness Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wellness No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Failure</title>
        <description>A treatment failure is defined as clinical deterioration or worsening of symptoms or illness continuing after 120 h following the first dose.</description>
        <time_frame>120 hours</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O2">
            <title>800 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O3">
            <title>1200 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Failure</title>
          <description>A treatment failure is defined as clinical deterioration or worsening of symptoms or illness continuing after 120 h following the first dose.</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Recovered From Diarrhoea</title>
        <description>Patients were considered to have recovered if fewer than three unformed stools were passed in the previous 24 hours and no symptom of enteric infection were present.</description>
        <time_frame>24 hours</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O2">
            <title>800 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
          </group>
          <group group_id="O3">
            <title>1200 mg Rifamycin SV Dosage</title>
            <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Recovered From Diarrhoea</title>
          <description>Patients were considered to have recovered if fewer than three unformed stools were passed in the previous 24 hours and no symptom of enteric infection were present.</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>400 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage</description>
        </group>
        <group group_id="E2">
          <title>800 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage</description>
        </group>
        <group group_id="E3">
          <title>1200 mg Rifamycin SV Dosage</title>
          <description>Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA™ version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC DISORDERS</sub_title>
                <description>Tachycardia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL DISORDERS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>GENERAL DISORDERS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>PSYCHIATRIC DISORDERS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN AND SUBCUTANEOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No disclosure was to take place without written authorisation from Cosmo Technologies Ltd, except to the extent necessary to obtain informed consent from potential volunteers.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Jones</name_or_title>
      <organization>Cosmo Technologies Ltd.</organization>
      <phone>+353 18170370</phone>
      <email>RJones@cosmopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

